Knockdown of EIF5A2 inhibits the malignant potential of non-small cell lung cancer cells

Abstract

Abstract. Eukaryotic translation initiation factor 5A2(EIF5A2) has been demonstrated to be upregulated in numerous types of human cancer and is associated with cancer progression. However, the expression and role of EIF5A2 in non-small cell lung cancer (NSCLC) remains unclear. In the present study, the role of EIF5A2 in NSCLC was investigated, in addition to the underlying molecular mechanisms by which EIF5A2 acts. Relative EIF5A2 expression levels were determined in NSCLC cells and compared with levels in non-cancerous lung tissues. Short interfering (si)RNA targeted against EIF5A2 was used to knock down EIF5A2 levels in NSCLC cells. Cell proliferation, apoptosis rate, migration ability and invasion ability were determined in untreated and siRNA-treated NSCLC cells, in addition to the relative protein expression levels of various tumorigenic proteins and E-cadherin. EIF5A2 expression was significantly higher in NSCLC tissues compared with adjacent normal tissues. Knockdown of EIF5A2 in the NSCLC cells significantly inhibited cell proliferation and induced apoptosis. Furthermore, EIF5A2 silencing suppressed cell migratory and invasive capacities in vitro. Silencing of EIF5A2 in the NSCLC cells resulted in the downregulation of the tumorigenic proteins, apoptosis regulator Bcl-2 and myc proto-oncogene protein, and upregulation of E-cadherin, suggesting that EIF5A2 promotes proliferation and metastasis through these proteins. EIF5A2 may therefore serve as a novel therapeutic target for the treatment of NSCLC.

Overexpression of EIF5A2 Predicts Poor Prognosis in Patients with Oral Squamous Cell Carcinoma

“…Unlike most members of the EIF5A family that are universally expressed, EIF5A2 is tissue specific to the testis, brain, and tumor cells, especially in ovarian and colorectal cancer cell lines [ 9 , 13 ]. EIF5A2 has been reported to be associated with ovarian cancer, colorectal carcinoma, hepatocellular carcinoma, breast cancer, bladder cancer, non-small cell lung cancer, gastric cancer, prostate cancer, and nasopharyngeal carcinoma [ 8 , 9 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ].…”

Finding new cancer epigenetic and genetic biomarkers from cell-free DNA by combining SALP-seq and machine learning

“…Furthermore, elevated expression of WHSC1 is often observed in many types of human cancers, and expression product of WHSC1 is essential for the growth of cancer cells [52] , [53] . The gene EIF5A2 was related to not only ESCA [54] , [55] , [56] , but also breast cancer [57] , lung cancer [58] , [59] , bladder cancer [60] , [61] , stomach cancer [62] , [63] , oral cancer [64] , liver cancer [65] , and colorectal cancer [66] . By checking the expression of these genes detected in tumors (RNA-seq data in TCGA), most of these genes are significantly up-regulated in tumors ( Figs.…”

Finding new cancer epigenetic and genetic biomarkers from cell-free DNA by combining SALP-seq and machine learning: esophageal cancer as an example

“…Furthermore, elevated expression of WHSC1 is often observed in many types of human cancers, and expression product of WHSC1 is essential for the growth of cancer cells [52][53][54] . The gene EIF5A2 was related to not only ESCA [55][56][57] , but also breast cancer 58 , lung cancer 59,60 , bladder cancer 61,62 , stomach cancer [63][64][65] , oral cancer 66 , liver cancer 67 , and colorectal cancer 68 . By checking the expression of these genes detected in tumors (RNA-seq data in TCGA), most of these genes are significantly up-regulated in tumors ( Fig.…”